Asset Details
Do you wish to reserve the book?
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
Do you wish to request the book?
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
2013
Overview
In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing–remitting multiple sclerosis (RRMS). This study analyzed fingolimod efficacy compared with IFNβ-1a in patient subgroups from TRANSFORMS. Patients were randomized to receive fingolimod or weekly IM IFNβ-1a for 12 months. Analyses of efficacy included annualized relapse rate (ARR), and magnetic resonance imaging (MRI) measures [gadolinium (Gd)-enhancing T1 lesions, new/newly enlarged (active) T2 lesions, brain volume change]. Subgroups were defined based on demographics, disease characteristics (baseline EDSS score, relapse rate, and MRI parameters), and response to previous therapy. Fingolimod 0.5 mg reduced ARR over 12 months by 32–59 % relative to IFNβ-1a in all subgroups defined by demographic factors or baseline disease characteristics. Fingolimod also reduced the number of new Gd-enhancing lesions, active T2 lesions, and the rate of brain volume loss, versus IFNβ-1a in most (95 %) subgroups. In patients with high disease activity despite IFNβ treatment in the year before study, fingolimod 0.5 mg reduced ARR by 61 % relative to IFNβ-1a. Reductions in lesion counts and brain volume loss also favored fingolimod in these patients. In conclusion, consistently better efficacy was observed for fingolimod compared with IFNβ-1a across different subgroups of patients with RRMS.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Brain
/ Data Interpretation, Statistical
/ Female
/ Humans
/ Image Processing, Computer-Assisted
/ Immunosuppressive Agents - administration & dosage
/ Immunosuppressive Agents - therapeutic use
/ Interferon-beta - administration & dosage
/ Interferon-beta - therapeutic use
/ Male
/ Medicine
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - physiopathology
/ Patients
/ Propylene Glycols - administration & dosage
/ Propylene Glycols - therapeutic use
/ Sphingosine - administration & dosage
/ Sphingosine - analogs & derivatives
